MYO
Myomo, Inc.
MYO offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR
Oscar Health, Inc.
OSCR has the edge over MYO overall, supported by stronger fundamentals and lower modeled downside.
MYO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Unavailable |
MYO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MYO PE Valuation
MYO has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MYO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect MYO's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
MYO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.35 | -$0.07 |
| Q2 2026 | -$0.34 | -$0.12 |
| Q1 2026 | -$0.36 | -$0.22 |
| Q4 2025 | -$0.37 | -$0.21 |
| Q3 2025 | -$0.28 | -$0.05 |
| Q2 2025 | -$0.22 | +$0.04 |
| Q1 2025 | -$0.14 | +$0.13 |
| Q4 2024 | -$0.16 | +$0.12 |
MYO is still losing money, but far less than before: $0.35 per share over the past year, against $19.35 at its worst in late 2019.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MYO on earnings quality, reporting a profit while its opponent remains loss making.
MYO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $12.3M | +22% |
| Q2 2026 | $11.7M | +21% |
| Q1 2026 | $10.1M | +2.9% |
| Q4 2025 | $11.4M | -5.9% |
| Q3 2025 | $10.1M | +9.6% |
| Q2 2025 | $9.7M | +28% |
| Q1 2025 | $9.8M | +162% |
| Q4 2024 | $12.1M | +154% |
MYO's revenue is growing: $12M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | +21 points |
| Q2 2026 | -19% | +28 points |
| Q1 2026 | -31% | +4.6 points |
| Q4 2025 | -24% | -22 points |
| Q3 2025 | -35% | -25 points |
| Q2 2025 | -48% | -33 points |
| Q1 2025 | -36% | +68 points |
| Q4 2024 | -2% | +49 points |
MYO's operating margin was −14% last quarter, up 21 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MYO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MYO on profitability, with a higher operating margin.
MYO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.4M | +$1.5M |
| Q2 2026 | -$2M | +$8.1M |
| Q1 2026 | -$2.5M | +$822.4K |
| Q4 2025 | $98.1K | -96% |
| Q3 2025 | -$2.9M | -$1.1M |
| Q2 2025 | -$10.1M | -$8.1M |
| Q1 2025 | -$3.3M | -$42.2K |
| Q4 2024 | $2.5M | +$4.9M |
MYO has burned cash in almost every quarter: −$6M over the past year, against −$14M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MYO on cash generation, producing positive trailing cash flow while its opponent burns cash.
MYO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +873K shares |
| 1 year | +3.3% | +1.4M shares |
| 3 years | +24% | +8.3M shares |
| 5 years | +673% | +37.9M shares |
| Available history | +7768% | +43M shares |
MYO has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MYO Net Leverage
MYO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MYO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.9 | Neutral |
| Stochastic | 20.7 | Neutral |
MYO's weekly RSI is 48 (neutral) and its Stochastic is 21 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MYO PE vs Healthcare Sector
MYO has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MYO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.34 | 9.7% below |
| 20 week MA | $1.32 | 8.3% below |
| 50 week MA | $1.08 | 12% above |
| 100 week MA | $2.14 | 43% below |
| 200 week MA | $2.36 | 49% below |
MYO's trend is mixed: it's above one of its five weekly moving averages, and 49% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MYO on trend strength, trading above more of its moving averages.
MYO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.08 | $6.94 | -24% |
| 2021 | $6.94 | $7.90 | +14% |
| 2022 | $7.90 | $0.44 | -94% |
| 2023 | $0.44 | $5.01 | +1039% |
| 2024 | $5.01 | $6.37 | +27% |
| 2025 | $6.37 | $1.02 | -84% |
| 2026 YTD | $1.02 | $1.21 | +19% |
MYO's yearly returns have swung widely, from +1039% in 2023 to −94% in 2022. It's up 19% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MYO on returns for 2026, with the stronger performance.